Precision Therapeutics Inc (NASDAQ:POAI) Short Interest Up 36.5% in September

Precision Therapeutics Inc (NASDAQ:POAI) was the target of a large growth in short interest during the month of September. As of September 15th, there was short interest totalling 382,400 shares, a growth of 36.5% from the August 31st total of 280,200 shares. Based on an average trading volume of 1,460,000 shares, the days-to-cover ratio is currently 0.3 days. Approximately 2.9% of the company’s shares are short sold.

Separately, ValuEngine cut shares of Precision Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, September 1st.

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Bank of New York Mellon Corp acquired a new stake in shares of Precision Therapeutics during the first quarter valued at about $27,000. Csenge Advisory Group purchased a new position in shares of Precision Therapeutics during the 2nd quarter worth approximately $29,000. Virtu Financial LLC acquired a new stake in Precision Therapeutics in the 2nd quarter valued at approximately $37,000. Finally, Sabby Management LLC purchased a new stake in Precision Therapeutics in the second quarter valued at approximately $367,000. 7.01% of the stock is currently owned by institutional investors.

Shares of POAI stock traded down $0.00 during trading on Thursday, hitting $0.81. 411,339 shares of the stock traded hands, compared to its average volume of 985,481. The firm has a market capitalization of $12.55 million, a P/E ratio of -0.11 and a beta of 1.56. Precision Therapeutics has a 52-week low of $0.79 and a 52-week high of $5.39. The company has a debt-to-equity ratio of 0.09, a current ratio of 0.30 and a quick ratio of 0.28. The firm’s fifty day moving average price is $1.03 and its 200-day moving average price is $1.42.

Precision Therapeutics (NASDAQ:POAI) last posted its earnings results on Thursday, August 13th. The medical instruments supplier reported ($0.36) EPS for the quarter. The business had revenue of $0.18 million during the quarter. Precision Therapeutics had a negative net margin of 1,902.82% and a negative return on equity of 124.77%.

About Precision Therapeutics

Predictive Oncology Inc provides various healthcare products and services primarily in the United States. The company manufactures environmentally conscious systems for the collection and disposal of infectious fluids that result from surgical procedures and post-operative care. It offers the STREAMWAY Fluid Waste Management system that suctions surgical waste fluid from the patient using standard surgical tubing; and disposables.

Featured Article: How prevalent are 12b-1 fees?

Receive News & Ratings for Precision Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Precision Therapeutics and related companies with's FREE daily email newsletter.